Navigation Links
GenVec Reports Second Quarter 2011 Financial Results
Date:8/9/2011

GAITHERSBURG, Md., Aug. 9, 2011 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) today announced its financial results for the three months and six months ended June 30, 2011.  

"During the second quarter we made significant progress in key programs including our collaboration with Novartis to develop treatments for hearing loss and balance disorders," said Dr. Paul Fischer, President and Chief Executive Officer. "We enter the second half of 2011 with strong momentum and look ahead to achieving key objectives in this collaboration as well as in our vaccine programs including foot-and-mouth disease and respiratory syncytial virus."

Recent Events

  • In April, research was published describing how GenVec technology, utilizing a vector targeted to supporting cells and limited in expression to those cells, can be used to restore balance function in an animal model.
  • In May, we expanded our relationship with Merial, the animal health division of sanofi-aventis, to include the evaluation of our technology for use against swine diseases.
  • In May, we regained compliance with NASDAQ listing requirements.
  • At the Company's annual meeting in June, Adel A.F. Mahmoud, M.D., Ph.D. and Edward M. Connor, Jr., M.D. were elected to the Company's Board of Directors adding to the Board's expertise in the areas of infectious disease and vaccine development.

  • Financial Results for the Three and Six Months Ended June 30, 2011GenVec reported a net loss of $1.2 million ($0.10 per share) for the three months ended June 30, 2011 compared to a net loss of $4.2 million ($0.33 per share) in the comparable quarter of 2010. For the six months ended June 30, 2011, GenVec's net loss was $3.5 million ($0.27 per share) compared to a net loss of $8.9 million ($0.72 per share) for the six months ended June 30, 2010.  

    Revenues for the three-month and six-month periods ended June 30, 2011 were $4.7 million and $10.0 million, respectively, compared to revenues of $3.2 million and $6.1 million in the comparable prior year periods. The increase for the three-month and six-month periods ended June 30, 2011 is primarily due to revenue increases associated with our hearing program with Novartis of $1.4 million and $4.0 million, respectively.  The higher revenue under the Novartis agreement is a result of the increased work scope and effort in 2011 as compared to the 2010 period.  In addition, revenue associated with our animal health program has increased $0.6 million and $0.8 million, respectively, during the three and six month periods ended June 30, 2011 as compared to the comparable prior year periods due to increased work scope with DHS and licensing revenue and work performed under the Merial agreements.  Partially offsetting these increases is decreased revenue associated with our HIV program of $0.4 million and $1.0 million during the three and six month periods ended June 30, 2011 as compared to the comparable prior year periods due to decreased work scope.  

    Operating expenses were $6.0 million and $13.5 million for the three-month and six-month periods ended June 30, 2011, respectively, representing decreases of 19 percent and 11 percent as compared to $7.4 million and $15.1 million in the comparable prior year periods. The decrease in both periods is primarily due to lower clinical costs as a result of the termination of the PACT trial and to a lesser extent lower professional costs. In the six-month period ended June 30, 2011, these decreases are partially offset by increased manufacturing costs for our hearing loss program as compared to the comparable period in 2010.

    GenVec ended the second quarter of 2011 with $30.6 million in cash, cash equivalents, and short-term investments.  

    Financial Guidance"We anticipate revenues for 2011 will be between $20.0 million and $22.0 million. We currently project our cash burn to be between $6.0 million and $8.0 million for the 12 months ending June 30, 2012," commented GenVec's Senior Vice President and Chief Financial Officer, Douglas J. Swirsky.

    Webcast and Conference Call GenVec will hold a conference call today at 10:00 a.m. to discuss the Company's second quarter results. To listen to the live conference call, please dial 877-558-0567 (U.S. or Canada) or 706-643-4980 (international) and use Conference ID 84527868. An audio replay of the conference call will be available starting at 11:00 a.m. on August 9, 2011 through August 16, 2011. To listen to the audio replay, dial 855-859-2056 (U.S. or Canada) or 404-537-3406 (international) and use access code 84527868.

    To access the webcast or the replay, go to www.genvec.com, click on "Investors and Media," and click on "Events and Presentations."

    About GenVecGenVec is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss, balance disorders, and cancer; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus type 2 (HSV-2), dengue fever, influenza, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD). Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

    Cautionary Note Regarding Forward Looking StatementsStatements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding funding, grants, collaborations, revenues, cash burn rates, the development of products and the success of the collaboration with Novartis, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act.  GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to research and development activities; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of collaborators and third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations.  Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov.  These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.(Tables to follow)GenVec, Inc.Condensed Statements of Operations(in thousands, except per share data)

    (Unaudited)Three Months Ended June 30,Six Months Ended June 30,2011201020112010Revenues $  4,737

    $  3,182

    $  10,023

    $  6,120Operating expenses:   Research and development

    4,127

    5,134

    9,719

    10,879   General and administrative  

    1,860

    2,281

    3,782

    4,229Total operating expenses

    5,987

    7,415

    13,501

    15,108Loss from operations(1,250)

    (4,233)

    (3,478)

    (8,988)   Interest income, net

    12

    40

    24

    127   Other

      -

      -

      -

    (31)Net loss$ (1,238)

    $ (4,193)

    $ (3,454)

    $ (8,892)Net loss per share – basic and diluted $  (0.10)

    $  (0.33)

    $  (0.27)

    $  (0.72)Weighted average shares outstanding – basic and diluted12,918

    12,891

    12,916

    12,433GenVec, Inc.Selected Balance Sheet Information(in thousands)June 30, 2011December 31, 2010(Unaudited)Cash and investments$30,599$35,170Working capital

    28,883

    31,689Total assets

    34,574

    39,432Stockholders' equity

    29,748

    32,420Retail Investor and Media Contact: GenVec, Inc.

    Douglas J. Swirsky

    (240) 632-5510

    dswirsky@genvec.com

    Institutional Investor Contact:S.A. Noonan Communications

    Susan A. Noonan

    (212) 966-3650

    susan@sanoonan.com
    '/>"/>

    SOURCE GenVec, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. GenVec Elects Adel A.F. Mahmoud and Edward M. Connor, Jr. to Board of Directors
    2. GenVec to Host First Quarter 2011 Earnings Call and Webcast
    3. GenVec Reports Fourth Quarter and 2010 Year-End Financial Results
    4. GenVec Forms Collaboration With World-Leading Animal Health Company
    5. GenVec Reports Third Quarter 2010 Financial Results
    6. GenVec Receives Second-Year Funding From SAIC for HIV and Influenza Vaccine Development
    7. GenVec Receives National Cancer Institute Grant to Expand Cancer Program
    8. GenVec Announces Multiple Presentations at the American Society of Tropical Medicine and Hygiene Meeting
    9. Providence Service Corporation Reports Q2 2011 Results In Line With Expectations
    10. Pharmos Corporation Reports 2011 Second Quarter Results
    11. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
    (Date:6/23/2016)... June 23, 2016  In a startling report released today, ... residents by lacking a comprehensive, proven plan to eliminate prescription opioid ... ranking of how states are tackling the worst drug crisis in ... states – Kentucky , New Mexico ... . Of the 28 failing states, three – ...
    (Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
    Breaking Medicine Technology:
    (Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
    (Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
    (Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
    (Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
    (Date:6/24/2016)... ... June 24, 2016 , ... The Haute ... Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s newest ... world, and the most handsome men, look naturally attractive. Plastic surgery should be ...
    Breaking Medicine News(10 mins):